Treatment of dissecting cellulitis of the scalp with tumor necrosis factor inhibitors: a retrospective multicenter study.

Date publication

janvier 2023

Journal

Clinical and experimental dermatology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr AUBIN François

Tous les auteurs :
Alzahrani M, Coste V, Konstantinou MP, Reguiai Z, Villani A, Hotz C, Viguier M, Pruvost-Balland C, Dupuy A, Wolkenstein P, Brun A, Aubin F, Gallais Sérézal I,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36702808

Résumé

Although retinoids are considered as the most effective treatment, management of dissecting cellulitis of the scalp (DCS) is often challenging. A multicenter retrospective study was conducted to evaluate the efficacy of anti-TNF agents in treating DCS after failure of other conventional treatments. Twenty-six patients were included. After a mean treatment duration of 19 ± 21 months, the mean PGA score decreased by 56% as the number of abscesses (-89%), the number of inflammatory nodules (-70%), the mean NRS score for pain severity (-68%) and the mean DLQI (-29%). This study confirms the efficacy of anti-TNF agents in treating DCS patients resistant to conventional therapies.

Référence

Clin Exp Dermatol. 2023 01 26;: